Spero Therapeutics, Inc.

Stage 4 · Declining · week 14

As of Oct 22, 2026, Spero Therapeutics is in Stage 4, the downtrend phase, now in week 14 (since Jul 21, 2026). It closed at $1.13, 62.1% below its 52-week high and below its 200-day average, which is falling.

$1.13

-3.42% today

$65.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SPRO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S2 14w

S4 35w

S2 14w

S2 15w

S4 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 18w → S1 8w → S2 14w → S3 9w → S4 8w → S1 1w → S4 35w → S1 2w → S2 11w → S3 9w → S2 14w → S3 5w → S2 15w → S3 3w → S4 13w current

Total tracked: 166 weeks across 15 stage runs.

SPRO among Biotechnology365th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…365	SPROSpero Therapeutics, Inc.	Stage 4 · wk 14	22	−10.3%

vs 52W High

-62.1%

$1.10 lo$2.98 hi

62.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 14

1w13w26w

Week 14, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-44.2%

200 DMA: $2.03 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.32x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.3%

-5.0%

-59.6%

YTD

-51.9%

-52.3%

Scan Membership

Breakout Watch

Latest: 2025-06-11

7 appearances in last 60 days. First seen: 2019-03-18.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 14 · Vol 0.32x

2026-10-21S4

Wk 14 · Vol 0.41x

2026-10-20S4

Wk 13 · Vol 1.10x

2026-10-19S4

Wk 13 · Vol 0.33x

2026-10-16S4

Wk 13 · Vol 0.57x

2026-10-15S4

Wk 13 · Vol 0.36x

2026-10-14S4

Wk 13 · Vol 1.08x

2026-10-13S4

Wk 12 · Vol 0.41x

2026-10-12S4

Wk 12 · Vol 0.61x

2026-10-09S4

Wk 12 · Vol 0.65x

2026-10-08S4

Wk 12 · Vol 1.05x

2026-10-07S4

Wk 12 · Vol 0.33x

Moving averages & range

50 DMA

$1.19

200 DMA

$2.03

52W High

$2.98

52W Low

$1.10

5D Low

$1.10

Resistance levels (recent highs)

20d High

$1.26

60d High

$1.36

120d High

$2.98

250d High

$2.98

Next resistance

+11.5%

to 20d High

P/E (TTM)

8.1

Forward -1.0

ROE

+19.2%

Profit margin +15.7%

Dividend Yield

0.00%

P/B 1.5

Spero Therapeutics: quick answers

What stage is Spero Therapeutics in?

As of Oct 22, 2026, Spero Therapeutics (SPRO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 21, 2026 and is in week 14. What the four stages mean

Is Spero Therapeutics in an uptrend?

No. Spero Therapeutics is in a Stage 4 downtrend. It trades 44.2% below its 200-day average, which is falling.

How far is Spero Therapeutics from its 52-week high?

Spero Therapeutics closed at $1.13 on Oct 22, 2026, 62.1% below its 52-week high of $2.98. Its 52-week low is $1.10.

How has Spero Therapeutics performed over the past year?

As of Oct 22, 2026, Spero Therapeutics is down 52.3% over the past year and down 51.9% so far in 2026.

Which sector and industry is Spero Therapeutics in?

Spero Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.